Photo courtesy of PursueCare

照片由Purseecare提供

PursueCare, a company that provides personalized virtual addiction treatment, announced the re-release of FDA-cleared RESET and RESET-O, prescription digital therapeutics for substance use disorder and opioid use disorder.

提供个性化虚拟成瘾治疗的追踪公司宣布重新发布FDA批准的RESET和RESET-O，即药物使用障碍和阿片类药物使用障碍的处方数字治疗药物。

RESET and RESET-O were initially developed and commercialized by Pear Therapeutics, which filed for Chapter 11 bankruptcy last year. PursueCare acquired the digital therapeutics offerings in December, several months after Pear's assets were auctioned off.

RESET和RESET-O最初是由Pear Therapeutics开发和商业化的，该公司去年申请了第11章的破产保护。在Pear的资产被拍卖几个月后，Purseecare于12月收购了数字治疗产品。

According to PursueCare, the app-based digital therapies RESET and RESET-O provide a self-guided 12-week course of cognitive behavioral therapy whereby patients are motivated to complete lessons, comply with treatment and cease drug use.

根据PurseeCare的说法，基于应用程序的数字疗法RESET和RESET-O提供了一个为期12周的自我指导的认知行为疗法课程，患者有动力完成课程，遵守治疗并停止使用药物。

The company will leverage the PDTs jointly with its thorough virtual treatment offering, concentrating on value-based care arrangements with health plans.

该公司将利用PDTs及其全面的虚拟治疗服务，专注于基于价值的健康计划护理安排。

Additionally, PursueCare is establishing programs with partnering clinics to allow the delivery of RESET and RESET-O to their patients.

此外，PurseeCare正在与合作诊所建立计划，以允许向患者提供RESET和RESET-O。

RESET and RESET-O integrate with outpatient care to deliver uninterrupted support and customized progress tracking, according to PursueCare.

RESET和RESET-O与门诊护理相结合，提供不间断的支持和定制的进度跟踪。

Meanwhile, by enhancing patient engagement, the PDTs are designed to align with value-based care models prioritized by health plans.

同时，通过增强患者参与度，PDT旨在与健康计划优先考虑的基于价值的护理模式保持一致。

'At PursueCare, we are driven by the belief that everyone deserves accessible, high-quality care that meets them where they are and stays with them through their journey,' Nick Mercadante, founder and chief executive officer of PursueCare, said in a statement.

Purseecare创始人兼首席执行官尼克·梅卡丹特（NickMercadante）在一份声明中说：“在Purseecare，我们的信念是，每个人都应该得到可获得的高质量护理，在他们所在的地方与他们见面，并在他们的旅程中与他们相伴。”。

'RESET and RESET-O align perfectly with our mission. Digital therapeutics empower individuals to reclaim control over their health, advancing a new standard of care for chronic substance use disorder.'

“RESET和RESET-O完全符合我们的使命。

THE LARGER TREND

更大的趋势

Pear's initial claim to fame was the 2017 De Novo clearance of its substance abuse treatment reSET, which marked the first prescription digital therapeutic to receive the agency's blessing.

Pear最初声名鹊起是2017年重新批准其药物滥用治疗重置，这标志着第一个获得该机构祝福的处方数字治疗。

In 2018, reSET was the first software-only therapeutic cleared by the FDA.

2018年，reSET是FDA批准的第一个纯软件治疗药物。

Pear hit the public markets in late 2021 through a merger with a special purpose acquisition company, but the company's stock price generally declined.

Pear于2021年末通过与一家特殊目的收购公司的合并上市，但该公司的股价普遍下跌。

In quarter three of 2022, Pear reported $4.1 million in revenue and a $30.7 million net loss. The company also said it had approved more layoffs, affecting 59 employees, or about 22% of Pear's workforce at the end of September. It had previously laid off 25 workers over the summer.

2022年第三季度，Pear报告收入410万美元，净亏损3070万美元。该公司还表示，已批准更多裁员，截至9月底，共有59名员工受到影响，约占Pear员工总数的22%。此前，该公司在夏季解雇了25名工人。

Pear announced in March 2023 that it was exploring 'strategic alternatives,' including a possible company sale, merger or acquisition. It hired a financial advisor to look into actions that could 'maximize shareholder value,' including a potential sale, M&A, divestiture of assets, licensing or other strategic transactions..

Pear在2023年3月宣布，它正在探索“战略替代方案”，包括可能的公司出售、合并或收购。它聘请了一名财务顾问，研究可能“最大化股东价值”的行动，包括潜在的出售、并购、资产剥离、许可或其他战略交易。。

That same month, via a filing with the Securities and Exchange Commission, Pear withdrew its revenue and operating guidance for fiscal 2022 and 2023 and announced it wouldn't hold a fourth quarter and full-year earnings call.

同一个月，通过向美国证券交易委员会（SEC）提交的文件，Pear撤回了2022和2023财年的收入和运营指导，并宣布不会召开第四季度和全年收益电话会议。

In April 2023, Pear filed for Chapter 11 bankruptcy and announced it was seeking a sale of its business or assets but would continue its scaled-down operations during Chapter 11 as it sought a sale. Pear would use its available cash to fund its operations and costs post-petition.

2023年4月，Pear申请第11章破产，并宣布正在寻求出售其业务或资产，但在寻求出售时，将在第11章期间继续其规模缩小的业务。Pear将利用其可用现金为请愿后的运营和成本提供资金。

A month later, the assets of Pear Therapeutics were broken up and sold at auction for $6.05 million in the wake of a bankruptcy filing by the company in April.

一个月后，Pear Therapeutics的资产在4月份申请破产后被拆分并以605万美元的价格拍卖。

According to the court filing, Pear's assets were split between four bidders: Digital therapeutics company Click Therapeutics, Harvest BIO, sleep tech company Nox Health Group and health technology company Welt.

根据法院备案文件，Pear的资产由四家投标人分割：数字治疗公司Click therapeutics、Harvest BIO、sleep tech company Nox Health Group和Health technology company Welt。

Harvest Bio was the successful bidder of Pear's Invention Science Fund licenses and patents, as well as its assets related to schizophrenia, multiple sclerosis, depression, major depressive disorder and other pipeline assets.

Harvest Bio是Pear发明科学基金许可证和专利以及与精神分裂症、多发性硬化症、抑郁症、重度抑郁症和其他管道资产相关的资产的中标人。

Harvest also successfully purchased Pear's corporate trademarks, PearConnect, reSET and reSET-O assets. Harvest purchased the assets for an aggregate price of $2.03 million.

Harvest还成功收购了Pear的公司商标PearConnect、reSET和reSET-O assets。Harvest以203万美元的总价收购了这些资产。

In December of last year, PursueCare announced it completed a $20 million Series B funding round and acquired the digital therapeutics assets reSET and reSET-O, the products originally developed by Pear Therapeutics.

去年12月，Purseecare宣布完成了2000万美元的B轮融资，并收购了最初由Pear therapeutics开发的产品digital therapeutics assets reSET和reSET-O。

The HIMSS Healthcare Cybersecurity Forum is scheduled to take place October 31-November 1 in Washington, D.C. Learn more and register.

HIMSS医疗保健网络安全论坛定于10月31日至11月1日在华盛顿特区举行。了解更多信息并注册。

Tags: PursueCare, reSET, reSET-O, Pear Therapeutics, prescription digital therapeutics, substance use disorder, opioid use disorder

标签：追踪，重置，重置-O，Pear治疗，处方数字治疗，物质使用障碍，阿片类药物使用障碍

More regional news

更多地区新闻

Parakeet Health raises $3M for expansion, developmentBy Anthony VecchioneOctober 16, 2024

Parakeet Health为扩张和发展筹集300万美元安东尼·维奇奥尼2024年10月16日

Oshi Health raises $60M for virtual GI platformBy Jessica HagenOctober 16, 2024

Oshi Health为虚拟GI平台筹集6000万美元Jessica Hagenober 162024

iCardio.ai gets FDA 510(k) clearance for AI echocardiography By Anthony VecchioneOctober 15, 2024

iCardio.ai获得FDA 510（k）批准AnthonyVecchione2024年10月15日进行人工智能超声心动图检查